Amphastar appoints Anthony Pierce to board, expands to 11 directors

Amphastar Pharmaceuticals, Inc.

Board increased from 10 to 11 directors; Anthony Pierce appointed as Class III director effective July 9, 2026.
Pierce is independent under Nasdaq standards; no committee assignments at this time.
Annual cash retainer of $55,000 (pro-rated); initial equity grant of $300,000 (50% RSUs, 50% options) vests on first anniversary.
Standard indemnification agreement to be entered with Pierce; no reportable transactions under Item 404(a).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.